{"id":"gnp","safety":{"commonSideEffects":[{"rate":"0.1-0.5%","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"0.01-0.05%","effect":"Genital amputations"},{"rate":"0.1-0.5%","effect":"Increased risk of acute kidney injury"},{"rate":"5-10%","effect":"Increased risk of hypotension"},{"rate":"5-10%","effect":"Increased risk of urinary tract infections"}]},"_chembl":null,"_dailymed":{"setId":"0bcc55bf-9654-120b-e063-6394a90a59d1","title":"GNP VAPOR STEAM CAMPHOR (SYNTHETIC) (CAMPHOR (SYNTHETIC)) LIQUID [AMERISOURCEBERGEN]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, GnP reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes, as it helps to lower HbA1c levels and reduce the risk of cardiovascular events.","oneSentence":"GnP is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:07.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"},{"name":"Reduction of major adverse cardiovascular events in patients with established cardiovascular disease or multiple cardiovascular risk factors"}]},"trialDetails":[{"nctId":"NCT07491445","phase":"PHASE3","title":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2026-03-09","conditions":"Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC","enrollment":900},{"nctId":"NCT07163273","phase":"PHASE2","title":"Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-06-20","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT07402122","phase":"","title":"Registry for Duchenne and Becker Muscular Dystrophy","status":"NOT_YET_RECRUITING","sponsor":"Dr. Andreas Ziegler","startDate":"2026-04","conditions":"Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Dystrophinopathy Symptomatic Female Carrier","enrollment":1500},{"nctId":"NCT07336953","phase":"PHASE3","title":"A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":198},{"nctId":"NCT06385925","phase":"PHASE1, PHASE2","title":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","status":"RECRUITING","sponsor":"Tyligand Pharmaceuticals (Suzhou) Limited","startDate":"2024-04-29","conditions":"Malignant Neoplasm","enrollment":440},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT07043270","phase":"PHASE2","title":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-09-29","conditions":"Pancreas Adenocarcinoma","enrollment":35},{"nctId":"NCT07101679","phase":"PHASE2","title":"A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-04-16","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma","enrollment":23},{"nctId":"NCT06991491","phase":"PHASE2","title":"Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-01","conditions":"Pancreatic Cancer","enrollment":29},{"nctId":"NCT04917848","phase":"NA","title":"A Study of a Telemedicine Program for Older Adults With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-06-01","conditions":"Cancer","enrollment":124},{"nctId":"NCT06532331","phase":"PHASE1","title":"A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2023-12-06","conditions":"Metastatic Pancreatic Cancer","enrollment":87},{"nctId":"NCT06483555","phase":"PHASE1, PHASE2","title":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-02-06","conditions":"Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm","enrollment":104},{"nctId":"NCT06868693","phase":"","title":"Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer","status":"NOT_YET_RECRUITING","sponsor":"Azienda Unita Sanitaria Locale di Piacenza","startDate":"2026-01-01","conditions":"Pancreatic Cancer Resectable, Pancreatic Cancer Stage II, Neoadjuvant Therapy","enrollment":240},{"nctId":"NCT05113862","phase":"PHASE1","title":"A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2","status":"COMPLETED","sponsor":"Gylden Pharma Ltd","startDate":"2022-01-10","conditions":"Coronavirus, SARS-CoV-2 Infection, COVID-19","enrollment":26},{"nctId":"NCT06538207","phase":"PHASE1","title":"An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-01-13","conditions":"Metastatic Pancreatic Cancer","enrollment":46},{"nctId":"NCT06398587","phase":"PHASE2","title":"Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-08-01","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":""},{"nctId":"NCT02837094","phase":"PHASE1","title":"Enhanced Epidermal Antigen Specific Immunotherapy Trial -1","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2016-09-29","conditions":"Type 1 Diabetes","enrollment":6},{"nctId":"NCT04935801","phase":"PHASE1","title":"A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus","status":"COMPLETED","sponsor":"Gylden Pharma Ltd","startDate":"2021-08-02","conditions":"Dengue","enrollment":26},{"nctId":"NCT05268692","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP","status":"RECRUITING","sponsor":"Kochi University","startDate":"2019-01-01","conditions":"Pancreatic Adenocarcinoma","enrollment":500},{"nctId":"NCT00000904","phase":"PHASE1","title":"Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00005758","phase":"PHASE3","title":"Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":472},{"nctId":"NCT00006291","phase":"PHASE2","title":"Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00011011","phase":"PHASE1, PHASE2","title":"Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-02","conditions":"HIV Infections","enrollment":94},{"nctId":"NCT00006495","phase":"PHASE1","title":"Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00026624","phase":"PHASE1","title":"Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00000879","phase":"PHASE1","title":"A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":48},{"nctId":"NCT00007332","phase":"PHASE2","title":"Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":330},{"nctId":"NCT00027261","phase":"PHASE1","title":"Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":110},{"nctId":"NCT00011037","phase":"PHASE2","title":"ALVAC-HIV vCP1452 Alone and Combined With MN rgp120","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":160},{"nctId":"NCT03476356","phase":"NA","title":"L-Carnitine and Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-11-01","conditions":"Polycystic Ovary Syndrome","enrollment":106},{"nctId":"NCT03401827","phase":"PHASE4","title":"The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2018-03-01","conditions":"Pancreatic Adenocarcinoma, Chemotherapy Effect","enrollment":40},{"nctId":"NCT00006509","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT01416168","phase":"NA","title":"Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2008-12","conditions":"Colorectal Cancer","enrollment":15},{"nctId":"NCT00013663","phase":"PHASE2","title":"Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3061,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"GnP","genericName":"GnP","companyName":"West China Hospital","companyId":"west-china-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GnP is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes, Reduction of major adverse cardiovascular events in patients with established cardiovascular disease or multiple cardiovascular risk factors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}